1. It also significantly reduced the number of active lesions in the experimental group, compared to those in a control group. 2. It also significantly reduced the number of active lesions in the patients who took the drug in tests against a control group. 3. It also significantly reduced the number of active lesions in patients, compared to other patients in a control group. 4. It also significantly reduced the number of active lesions in the patients compared to those in a control group. 5. Those who are diagnosed with a late-onset progressive disease show abnormalities of the brain, but only a few active inflammatory lesions. |
|